ReviewiLIVER2022
Latest innovations in the treatment of Wilson's disease.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cuproptosis and the bioinorganic basis of copper-induced cell death.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026Review
- Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase.Orphanet journal of rare diseases · 2026Article
- Wilson's Disease-Crossroads of Genetics, Inflammation and Immunity/Autoimmunity: Clinical and Molecular Issues.International journal of molecular sciences · 2024Review
- Systematic Analysis and Insights Into the Mutation Spectrum and Ethnic Differences in ATP7B Mutations Associated With Wilson Disease.Biomarker insights · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wilson's disease (WD), also called hepatolenticular degeneration, is an autosomal recessive copper dysfunction disorder that is among the few treatable neurogenetic disorders. The main goals for controlling WD are to lower copper intake and encourage copper removal. Medical treatments and low-copper diets are available, but many problems remain. For example, the current treatments cannot fix copper metabolism and are unable to cross the blood-brain barrier. Furthermore, severe side effects have been experienced by many patients with WD. Because lifelong therapy is required for this disease, adherence to medical therapy and best practices for monitoring and personalizing therapy continue to evolve; some of these issues are being addressed in ongoing studies. Additionally, novel chelating agents, gene therapies using adeno-associated viruses, and variant-specific therapies that may improve neurological outcomes are in development. Here, we review the latest treatment innovations that may play an essential role for patients with WD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.